Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)
NCT01747083 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2013-10-24
Summary
This study is designed to investigate the food-effects on FDC(gemigliptin/metformin HCl sustained release) 50/1000mg(25/500mg x 2tablets)
Conditions
Interventions
- DRUG
-
FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))
Sponsors & Collaborators
-
LG Life Sciences
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 20 Years
- Max Age
- 45 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-01-31
- Primary Completion
- 2013-03-31
- Completion
- 2013-04-30
Countries
- South Korea
Study Locations
More Related Trials
-
BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone
NCT02670018 ·Status: UNKNOWN ·Phase: PHASE1
-
A Comparitive Bioavailability Study of Metformin Hydrochloride Liquid 500mg/ 5 mL Under Fasting Conditions and After Low and High Fat Meal
NCT00778349 ·Status: COMPLETED ·Phase: NA
-
Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting Conditions
NCT04070794 ·Status: UNKNOWN ·Phase: PHASE1
-
Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers
NCT01561976 ·Status: COMPLETED ·Phase: NA
-
A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal
NCT07333742 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers
NCT01216397 ·Status: COMPLETED ·Phase: PHASE1
-
Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d
NCT01787396 ·Status: COMPLETED ·Phase: PHASE3
-
BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone
NCT01662674 ·Status: COMPLETED ·Phase: PHASE1
-
Fasting Bioequivalence Study of 2 Metformin 1000 mg Prolonged Release Tablets in 28 Healthy Male and Female Volunteers
NCT05123781 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs
NCT03787017 ·Status: COMPLETED ·Phase: PHASE1
-
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers
NCT01725672 ·Status: TERMINATED ·Phase: PHASE1
-
Fed Bioequivalence Study of 2 Metformin 1000 mg Prolonged Release Tablets in 28 Healthy Male and Female Volunteers
NCT05125575 ·Status: COMPLETED ·Phase: PHASE1
-
A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions
NCT00865033 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets
NCT01975220 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
NCT02221180 ·Status: COMPLETED ·Phase: PHASE1
-
Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets
NCT01845077 ·Status: COMPLETED ·Phase: PHASE1
-
Fasting Bioequivalence Study of 2 Metformin 500 mg Prolonged Release Tablets in 44 Healthy Male and Female Volunteers
NCT05124730 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin
NCT01540487 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
NCT01211197 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin
NCT01376323 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects.
NCT01443221 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants
NCT02220218 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers
NCT01463228 ·Status: COMPLETED ·Phase: PHASE1
-
A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions
NCT00865852 ·Status: COMPLETED ·Phase: PHASE1
-
Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State
NCT01002807 ·Status: COMPLETED ·Phase: PHASE1